Stock listing

OTC:ADAPY Adaptimmune Therapeutics PLC Stock

Follow Adaptimmune Therapeutics PLC into a list and get an email when it puts out news.

Share price · OTC:ADAPY

$0.03 USD 0.00 (0.0%)

Close on Nov 20, 2026

Past year -40.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.024 – $0.03 USDNov 20, 2026
Volume
830,169 sharesNov 20, 2026
Market cap
$7.95M USDAt the close on Nov 20, 2026 · price × 265.1M shares outstanding
52-week range
$0.0001 – $0.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7,929 USDMedian day 167,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Adaptimmune Therapeutics PLC logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ADAPY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.030.000.0%$0.024$0.03$0.024830,169
$0.03+0.006+25.0%$0.029$0.033$0.029514,817
$0.024-0.008-25.0%$0.023$0.035$0.021433,300
$0.032-0.001-3.0%$0.021$0.033$0.021175,000
$0.033+0.003+10.0%$0.03$0.033$0.0211,255,000
$0.03+0.002+7.1%$0.02$0.03$0.02119,200
$0.028-0.002-6.7%$0.013$0.03$0.013166,700
$0.03+0.012+66.7%$0.018$0.03$0.0182,527,100
$0.018-0.007-28.0%$0.018$0.025$0.018246,200
$0.025+0.005+25.0%$0.017$0.025$0.017120,700
$0.02+0.001+5.3%$0.017$0.025$0.017168,000
$0.019-0.001-5.0%$0.018$0.024$0.017826,400
$0.02-0.005-20.0%$0.03$0.03$0.01879,000
$0.025-0.002-7.4%$0.018$0.027$0.018342,900
$0.027+0.004+17.4%$0.021$0.028$0.02289,600
$0.023-0.003-11.5%$0.029$0.029$0.02577,000
$0.026-0.003-10.3%$0.029$0.029$0.025144,700
$0.0290.000.0%$0.025$0.029$0.02545,800
$0.029+0.004+16.0%$0.025$0.03$0.02543,800
$0.025-0.005-16.7%$0.025$0.03$0.025340,800
$0.03+0.005+20.0%$0.032$0.032$0.02542,000
$0.025-0.007-21.9%$0.028$0.033$0.02628,900
$0.032-0.001-3.0%$0.028$0.033$0.028187,700
$0.033-0.002-5.7%$0.028$0.033$0.02880,300
$0.035+0.003+9.4%$0.02$0.035$0.0258,700
$0.032-0.001-3.0%$0.031$0.033$0.027164,700
$0.033+0.003+10.0%$0.028$0.037$0.022558,300
$0.03+0.001+3.4%$0.028$0.03$0.023212,200
$0.029-0.001-3.3%$0.028$0.03$0.028108,000
$0.030.000.0%$0.028$0.03$0.02887,700
$0.03+0.002+7.1%$0.026$0.032$0.02677,400
$0.0280.000.0%$0.022$0.028$0.02250,900
$0.028-0.001-3.4%$0.022$0.029$0.02137,000
$0.029-0.001-3.3%$0.021$0.03$0.021282,000
$0.03-0.007-18.9%$0.02$0.037$0.02221,400
$0.037-0.001-2.6%$0.02$0.039$0.0264,800
$0.0380.000.0%$0.04$0.04$0.027229,500
$0.038+0.012+46.2%$0.0010$0.039$0.00101,351,800
$0.026-0.001-3.7%$0.018$0.027$0.01893,800
$0.027+0.001+3.8%$0.019$0.027$0.018311,100
$0.026+0.003+13.0%$0.019$0.026$0.019123,100
$0.023-0.003-11.5%$0.026$0.026$0.017264,900
$0.0260.000.0%$0.026$0.026$0.02344,500
$0.026-0.001-3.7%$0.017$0.027$0.017121,900
$0.027+0.004+17.4%$0.02$0.027$0.02452,300
$0.0230.000.0%$0.01$0.023$0.0186,500
$0.023-0.002-8.0%$0.025$0.025$0.01869,900
$0.0250.000.0%$0.02$0.026$0.018242,200
$0.025+0.001+4.2%$0.018$0.027$0.018228,700
$0.024+0.001+4.3%$0.02$0.025$0.02188,000
$0.0230.000.0%$0.02$0.026$0.0294,500
$0.023-0.002-8.0%$0.02$0.027$0.0263,200
$0.025-0.001-3.8%$0.026$0.026$0.021222,700
$0.026-0.001-3.7%$0.021$0.027$0.0268,100
$0.027+0.001+3.8%$0.022$0.027$0.02192,700
$0.026+0.001+4.0%$0.02$0.027$0.005082,900
$0.025-0.002-7.4%$0.021$0.027$0.02162,800
$0.027+0.004+17.4%$0.02$0.027$0.02212,300
$0.023-0.005-17.9%$0.023$0.028$0.023277,600
$0.028-0.001-3.4%$0.029$0.029$0.023276,500
$0.029+0.003+11.5%$0.029$0.029$0.023198,300
$0.026+0.001+4.0%$0.024$0.029$0.024166,800
$0.025-0.001-2.3%$0.014$0.03$0.014146,005
$0.026-0.001-5.2%$0.027$0.03$0.026246,249
$0.0270.000.0%$0.027$0.03$0.02795,200
$0.0270.000.0%$0.025$0.029$0.025156,000
Ticker
OTC:ADAPY
Asset type
Stock
Exchange
OTC
Currency
USD

Adaptimmune Therapeutics PLC on 6ix

Calls
9 calls with a replay · 9 with a transcript · latest May 13, 2025
Decks
10 decks · latest May 6, 2019

Valuation

balance Jun 30, 2025 · price Nov 20, 2026

Enterprise value
$7.57M USD
P/E
Not reported
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
-1.10

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
0.68 USD · Analysts' mean
EPS, year to Dec 2025
-0.47 · 1 analyst

Team and board

Officers

OfficerRole
Christopher HillChief Executive Officer and Chief Financial Officer

Board

DirectorRole
Lawrence M. AllevaChairman and Non-Executive Director
Garry MenzelNon-Executive Director

Events

Results days

QuarterResultsShare move
Quarter to Mar 31, 2026Apr 23, 2026 · After close0.0%
Quarter to Dec 31, 2025Mar 10, 2026+50.0%
Quarter to Sep 30, 2025Nov 28, 2025−5.1%
Q2 2025Aug 13, 2025 · Before open+1.3%
Q1 2025May 13, 2025−7.8%
Q4 2024Mar 24, 2025 · After close−9.8%
Q3 2024Nov 13, 2024 · After close−23.4%
Q2 2024Aug 12, 2024 · Before open+9.8%
Q1 2024May 15, 2024+4.3%
Q4 2023Mar 6, 2024 · Before open+17.1%
All 20 quarters
QuarterResultsShare move
Q3 2023Nov 8, 2023 · Before open−5.5%
Q2 2023Aug 9, 2023 · Before open−1.2%
Q1 2023May 12, 2023 · After close+1.5%
Q4 2022Mar 6, 2023−29.0%
Q3 2022Nov 8, 2022 · After close+1.0%
Q2 2022Aug 4, 2022 · After close+0.9%
Q1 2022May 9, 2022 · Before open−9.9%
Q4 2021Mar 14, 2022−5.0%
Q3 2021Nov 4, 2021 · Before open−4.0%
Q2 2021Aug 9, 2021 · After close+3.5%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (May 2019)Corporate update40 slidesMay 6, 2019
Technical Presentation (June 2017)Technical13 slidesJun 6, 2017
Investor Presentation (April 2017)Investor deck32 slidesApr 10, 2017
Investor Presentation (March 2017)Investor deck31 slidesMar 14, 2017
J.P. Morgan Healthcare Conference 2017Conference40 slidesJan 9, 2017
Investor Presentation (December 2015)Investor deck30 slidesDec 15, 2015
Jefferies Autumn Global Healthcare Conference 2015Conference42 slidesNov 18, 2015
Investor Presentation (November 2015)Investor deck34 slidesNov 18, 2015
Investor Presentation (October 2015)Investor deck32 slidesOct 19, 2015
Investor Presentation (September 2015)Investor deck30 slidesSep 15, 2015

Open Decks

IPO

Priced at US$17.00 an ADS on May 5, 2015.

Price
US$17.00 an ADS
ADSs offered
11,250,000 American depositary shares
Offering size
US$191.3 million
Underwriters' option
Up to 1,687,500 more ADSs
Listing
ADAP on the Nasdaq Global Select Market
Underwriters
BofA Merrill Lynch, Cowen and Company, Leerink Partners, Guggenheim Securities · In the order on the cover
ADSs delivered
On or about May 11, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 5, 2015
Filed publiclyApr 6, 2015
Amended twiceNewest May 1, 2015
Shares registered with an exchangeApr 30, 2015
Declared effective by the SECMay 5, 2015
Final prospectus, with the priceMay 7, 2015

Open IPO · From the cover of the final prospectus (424B4) filed May 7, 2015

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue178.0M60.3M27.1M6.15M3.96M1.12M59.5M37.8M14.2M9.87M
Cost of revenue70.0K
Gross profit178.0M
Research and development149.1M126.5M127.7M111.1M91.6M97.5M98.3M87.4M63.8M24.1M
Selling, general and administrative87.3M73.5M63.4M
Operating income-68.8M-139.7M-164.0M-162.2M-133.4M-139.8M-82.4M-80.7M-72.8M-24.6M
Depreciation and amortization10.8M9.45M5.27M5.63M6.63M7.17M7.19M5.03M3.13M705.0K
EBITDA-57.9M-130.3M-158.7M-156.6M-126.8M-132.6M-75.2M-75.6M-69.7M-23.9M
Interest expense3.35M
Income before tax-67.2M-112.5M-163.0M-157.3M-129.9M-136.9M-95.0M-69.7M-70.7M-21.8M
Income tax3.58M1.34M2.50M791.0K162.0K242.0K497.0K451.0K892.0K244.0K
Net income-70.8M-113.9M-165.5M-158.1M-130.1M-137.2M-95.5M-70.1M-71.6M-22.1M
Earnings per share, basic-0.05-0.09-0.17-0.17-0.15-0.22-0.16-0.13-0.17-0.17
Earnings per share, diluted-0.05-0.09-0.17-0.17-0.15-0.22-0.16-0.13-0.17-0.17

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash and equivalents91.1M144.0M108.0M149.9M56.9M50.4M68.4M84.0M158.8M229.0M
Short-term investments60.5M2.95M96.6M219.6M311.3M39.1M136.8M124.2M
Receivables1.45M821.0K7.43M752.0K139.0K192.0K206.0K1.48M4.00K
Inventory7.32M
Current assets188.2M207.6M255.4M415.5M398.2M120.5M231.1M230.2M198.8M295.1M
Property, plant and equipment31.3M50.9M53.5M30.5M27.8M31.1M36.1M40.7M27.9M5.39M
Total assets246.0M282.6M328.9M469.5M451.1M181.5M276.7M281.1M234.5M300.7M
Accounts payable8.69M8.13M4.75M8.11M6.39M6.36M4.08M8.38M11.3M1.98M
Current liabilities64.5M72.8M64.5M62.5M39.1M34.3M24.4M74.3M40.3M26.8M
Long-term debt50.2M
Total debt54.3M
Total liabilities234.1M243.1M247.0M263.6M109.9M57.9M29.9M78.2M68.4M41.6M
Shareholders' equity11.8M39.5M81.9M206.0M341.2M123.6M246.9M203.0M166.1M259.0M
Shares outstanding1.54B1.36B987.1M928.5M928.8M631.0M627.5M562.1M424.8M424.7M

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations-73.2M-140.9M-141.8M10.7M-53.6M-112.5M-104.4M-54.3M-48.2M-29.7M
Capital spending-886.0K-4.68M-29.5M-8.57M-2.34M-1.59M-3.91M-24.6M-11.5M-5.08M
Free cash flow-74.1M-145.6M-171.3M2.15M-55.9M-114.1M-108.3M-79.0M-59.7M-34.7M
Cash from investing-59.0M176.5M89.1M75.8M-278.9M94.9M-17.5M-126.1M17.8M-58.8M
Cash from financing78.7M880.0K12.9M3.29M340.1M366.0K102.7M103.6M17.0K274.9M
Change in cash-53.8M37.4M-42.1M90.2M6.58M-17.6M-15.8M-74.5M-36.0M177.9M

Open Financials

Filings

FilingDateTypeFiled with
RW · Request to withdraw a registrationApr 22, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
424B3 · ProspectusNov 13, 2025Offer documentSEC
15-12GNov 13, 2025Other filingsSEC
S-8 POSOct 28, 2025Offer documentSEC
S-8 POSOct 28, 2025Offer documentSEC
S-8 POSOct 28, 2025Offer documentSEC
POS AM · Amendment to an effective registrationOct 28, 2025Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
25Oct 28, 2025Other filingsSEC
8-K · Current reportOct 20, 2025Current reportSEC
3 · Initial statement of ownershipOct 8, 2025Insider tradeSEC
8-K · Current reportSep 26, 2025Current reportSEC
8-K · Current reportSep 12, 2025Current reportSEC
8-K · Current reportSep 8, 2025Management or board changeSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
144 · Notice of proposed saleSep 2, 2025Other filingsSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
144 · Notice of proposed saleAug 29, 2025Other filingsSEC
8-K · Current reportAug 29, 2025Management or board changeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 19, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 19, 2025Big-stake noticeSEC
8-K · Current reportAug 15, 2025Management or board changeSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
8-K · Current reportAug 14, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
8-K · Current reportAug 7, 2025Management or board changeSEC
8-K · Current reportJul 31, 2025Acquisition or disposalSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
8-K · Current reportJul 28, 2025Material contractSEC
8-K · Current reportJul 17, 2025Current reportSEC
8-K · Current reportMay 29, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
8-K · Current reportMay 1, 2025Current reportSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
S-3 · Registration statementApr 18, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementApr 15, 2025Meeting noticeSEC
8-K · Current reportApr 14, 2025Management or board changeSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
8-K · Current reportMar 24, 2025Material contractSEC
8-K · Current reportMar 20, 2025ResultsSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
144 · Notice of proposed saleJan 17, 2025Other filingsSEC
144 · Notice of proposed saleJan 17, 2025Other filingsSEC
144 · Notice of proposed saleJan 17, 2025Other filingsSEC
144 · Notice of proposed saleJan 17, 2025Other filingsSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2025Big-stake noticeSEC
8-K · Current reportDec 19, 2024Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 5, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportNov 13, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
8-K · Current reportNov 1, 2024Current reportSEC
8-K · Current reportSep 23, 2024Material contractSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
8-K · Current reportAug 2, 2024Current reportSEC
8-K · Current reportJul 16, 2024Management or board changeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
8-K · Current reportJun 11, 2024Management or board changeSEC
8-K · Current reportMay 30, 2024Material contractSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
8-K · Current reportMay 15, 2024Material contractSEC
8-K · Current reportMay 14, 2024Meeting outcomeSEC
ARS · Annual report to shareholdersApr 22, 2024Annual reportSEC
8-K · Current reportApr 12, 2024Current reportSEC
DEF 14A · Proxy statementApr 11, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedApr 2, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 1, 2024Meeting noticeSEC
3 · Initial statement of ownershipMar 26, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedMar 26, 2024Big-stake noticeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
10-K · Annual reportMar 6, 2024Annual reportSEC
8-K · Current reportMar 6, 2024ResultsSEC
8-K · Current reportFeb 27, 2024Management or board changeSEC
8-K · Current reportFeb 16, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
8-K · Current reportJan 31, 2024Current reportSEC
SC 13G · Big-stake noticeJan 30, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 29, 2024Big-stake noticeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 12, 2024Insider tradeSEC
4 · Change in ownershipJan 12, 2024Insider tradeSEC
4 · Change in ownershipJan 12, 2024Insider tradeSEC
4 · Change in ownershipJan 12, 2024Insider tradeSEC
8-K · Current reportJan 4, 2024Current reportSEC
8-K · Current reportDec 6, 2023Current reportSEC
S-8 · Registration statement for employee plansNov 30, 2023Offer documentSEC
8-K · Current reportNov 14, 2023Current reportSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
SC 13G · Big-stake noticeNov 8, 2023Big-stake noticeSEC
8-K · Current reportNov 8, 2023ResultsSEC
8-K · Current reportNov 3, 2023Management or board changeSEC
3 · Initial statement of ownershipNov 1, 2023Insider tradeSEC
8-K · Current reportOct 31, 2023Current reportSEC
4 · Change in ownershipSep 1, 2023Insider tradeSEC
8-K · Current reportAug 31, 2023Current reportSEC
8-K/A · Current report, amendedAug 10, 2023Current reportSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportAug 9, 2023ResultsSEC
4 · Change in ownershipAug 1, 2023Insider tradeSEC
4 · Change in ownershipJul 10, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2023Big-stake noticeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
S-8 POSJun 29, 2023Offer documentSEC
S-8 POSJun 29, 2023Offer documentSEC
8-K · Current reportJun 29, 2023Management or board changeSEC
4 · Change in ownershipJun 27, 2023Insider tradeSEC
4 · Change in ownershipJun 1, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 1, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 1, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 1, 2023Insider tradeSEC
8-K · Current reportJun 1, 2023Acquisition or disposalSEC
425May 30, 2023Other filingsSEC
8-K · Current reportMay 30, 2023Meeting outcomeSEC
425May 22, 2023Other filingsSEC
8-K · Current reportMay 22, 2023Current reportSEC
8-K · Current reportMay 16, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
8-K · Current reportMay 12, 2023ResultsSEC
EFFECT · Notice that a registration is effectiveApr 21, 2023Other filingsSEC
424B3 · ProspectusApr 20, 2023Offer documentSEC
CORRESP · Letter to the SECApr 18, 2023Other filingsSEC
S-4/A · Registration statement, amendedApr 18, 2023Offer documentSEC
DEF 14A · Proxy statementApr 13, 2023Meeting noticeSEC
8-K · Current reportApr 11, 2023Material contractSEC
UPLOAD · Letter from the SECApr 6, 2023Other filingsSEC
S-4 · Registration statementApr 5, 2023Offer documentSEC
PRE 14A · Preliminary proxy statementApr 3, 2023Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedMar 30, 2023Big-stake noticeSEC
8-K · Current reportMar 10, 2023Current reportSEC
425Mar 9, 2023Other filingsSEC
425Mar 9, 2023Other filingsSEC
10-K · Annual reportMar 6, 2023Annual reportSEC
8-K · Current reportMar 6, 2023ResultsSEC
425Mar 6, 2023Other filingsSEC
8-K · Current reportMar 6, 2023Material contractSEC

This page holds 200 of 808 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Adaptimmune Therapeutics PLC’s releases

Common shares
265,051,591
Fully diluted
265,051,591

Fully diluted

LineShares
Common shares265,051,591

Share count over time

CountShares
Nov 22, 2026265,051,591

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ali Behbahani
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past)
Director · Since at least Jul 2, 2019
Lawrence M. Alleva
Other companies: Galera Therapeutics, Inc. (Director · Since at least Nov 6, 2019); Mersana Therapeutics Inc (Director · Since at least Sep 5, 2017); Bright Horizons Family Solutions Inc. (Board Member · Since at least May 12, 2016); Tesaro Inc (Director · Jun 1, 2016 – Jan 22, 2019 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past)
Chairman and Non-Executive Director · Since at least Jan 1, 2016
Rafael G. Amado
Other companies: Zai Lab Ltd. (President, Head of Global Research and Development · Since at least Dec 30, 2022); Poseida Therapeutics Inc (Director · Apr 13, 2023 – Jan 8, 2025 · Past); Allogene Therapeutics, Inc. (EVP of R&D · Sep 3, 2019 – Oct 7, 2022 · Past)
President, R&D · Jan 1, 2016 – Aug 6, 2019 · Past
James Noble
Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); GW Pharmaceuticals plc (Director · Oct 1, 2018 – May 5, 2021 · Past)
Director · Jan 1, 2016 – Jul 1, 2022 · Past
Michael Garone
Other companies: Immunomedics Inc (Chief Financial Officer · Jun 27, 2016 – Jul 3, 2017 · Past); Emisphere Technologies Inc (CFO · Mar 12, 2009 – Jan 14, 2016 · Past)
Interim CFO · Oct 1, 2019 – Oct 1, 2019 · Past
Cintia Piccina
Other companies: Autolus Therapeutics plc (U.S. CCO & Country Gen Manager · Since at least Mar 18, 2026)
Chief Commercial Officer · Mar 18, 2024 – Feb 20, 2025 · Past
Garry E. Menzel
Other companies: Black Diamond Therapeutics, Inc. (Operating Partner, GHO Capital Partners LLP · Since at least Nov 4, 2026)
Non-Executive Director · Since at least Nov 5, 2026
Gavin Wood
Other companies: Affymetrix Inc (EVP, Chief Financial Officer · May 20, 2013 – Mar 31, 2016 · Past)
Chief Financial Officer · Since at least Apr 1, 2020
William C Bertrand Jr
Other companies: Ardelyx, Inc. (Director · Since at least Jun 2, 2016)
Chief Operating Officer · Since at least Mar 15, 2017
Christopher HillChief Executive Officer and Chief Financial Officer · Since at least Nov 5, 2026
All 11 people
PersonSeat
Joanna Elizabeth BrewerChief Scientific Officer · May 4, 2022 – Feb 20, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Adaptimmune Therapeutics PLC.